Related Experiment Videos
Current medical therapy for inflammatory bowel disease
1Department of Gastroenterology, Cleveland Clinic Florida, Fort Lauderdale, FL 33309, USA.
Southern Medical Journal
|June 1, 1996
Summary
Newer mesalamine derivatives offer improved delivery and fewer side effects for inflammatory bowel disease (IBD) patients. Investigational steroids and immunosuppressive agents show promise for refractory IBD and severe ulcerative colitis management.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Traditional treatments for inflammatory bowel disease (IBD) include corticosteroids and sulfasalazine.
- Recent advancements have introduced mesalamine derivatives, enhancing medication delivery and reducing side effects.
Purpose of the Study:
- To review current and emerging therapies for inflammatory bowel disease (IBD).
- To highlight the benefits of newer drug formulations and immunosuppressive agents.
Main Methods:
- Literature review of traditional and novel IBD treatments.
- Analysis of efficacy and side effect profiles of various medications.
Main Results:
- Mesalamine derivatives allow higher dosages with fewer adverse effects.
- Investigational steroids may match prednisone efficacy with better tolerability.
- Immunosuppressants like 6-mercaptopurine, azathioprine, and methotrexate are effective for refractory IBD.
- Cyclosporine shows potential in delaying colectomy for severe ulcerative colitis.
Conclusions:
- Emerging IBD therapies offer improved efficacy and safety profiles.
- Further research is needed to establish the long-term role of agents like cyclosporine.